Understanding how cancer cells avoid immune detection after chemotherapy
Targeting mechanisms of immune evasion in chemotherapy-induced senescent cells
This study is looking at how some breast cancer cells manage to survive chemotherapy by hiding from the immune system, and it aims to find new ways to help the body get rid of these tricky cells to improve recovery for patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Tulane University of Louisiana NIH-funded |
| Lab location | 1 site (New Orleans, United States) |
| Project ID | NIH-11026373 on NIH RePORTER |
What this research studies
This research investigates how certain breast cancer cells survive chemotherapy by evading the immune system. It focuses on the role of senescent cells, which are tumor cells that have stopped dividing but can still promote cancer relapse. The researchers aim to identify mechanisms that allow these cells to avoid being cleared by the immune system and to develop new therapies that can target this evasion. By studying the interactions between these cells and their surrounding environment, the project seeks to improve patient outcomes after treatment.
Who could benefit from this research
Good fit: Ideal candidates for this research are breast cancer patients who have undergone chemotherapy and have p53 wild type tumors.
Not a fit: Patients with p53 mutant tumors or those who have not received chemotherapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that enhance the immune system's ability to eliminate residual cancer cells, potentially improving survival rates for patients.
How similar studies have performed: Other research has shown promising results in targeting immune evasion in cancer, suggesting that this approach could be effective.
Where this research is happening
New Orleans, United States
- Tulane University of Louisiana — New Orleans, United States (Active)
Researchers
- Principal investigator: Jackson, James — Tulane University of Louisiana
- Study coordinator: Jackson, James
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.